Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05249829
Recruitment Status : Recruiting
First Posted : February 22, 2022
Last Update Posted : April 18, 2022
Sponsor:
Information provided by (Responsible Party):
ModernaTX, Inc.

Brief Summary:
This is a 2-part study to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1273.529 and mRNA-1273.214 administered as a booster dose.

Condition or disease Intervention/treatment Phase
SARS-CoV-2 Biological: mRNA-1273.529 Biological: mRNA-1273 Biological: mRNA-1273.214 Phase 2 Phase 3

Detailed Description:

In Part 1, participants will be randomized in a 1:1 ratio to receive a single dose of either mRNA-1273.529 or mRNA-1273.

In Part 2, participants will be randomized in a 1:1 ratio to receive a single dose of either mRNA-1273.214 or mRNA-1273.

All participants will have previously received 2 or 3 doses of an authorized/approved COVID-19 vaccine. Participants who previously received 2 doses of a COVID-19 vaccine as a primary series will receive mRNA-1273.529, mRNA-1273.214, or mRNA-1273 as the 3rd dose, and participants who have previously received a primary series and 1 booster dose will receive mRNA-1273.529, mRNA-1273.214, or mRNA-1273 as the 4th dose (a mixed approach is acceptable).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 3924 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase 2/3, Randomized, Observer-blind, Active-controlled, Multicenter Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 (Prototype) Booster Vaccine
Actual Study Start Date : February 16, 2022
Estimated Primary Completion Date : April 7, 2023
Estimated Study Completion Date : April 7, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vaccines

Arm Intervention/treatment
Experimental: Part 1: mRNA-1273.529
Participants will receive 1 intramuscular (IM) dose of mRNA-1273.529 on Day 1.
Biological: mRNA-1273.529
Sterile liquid for injection

Active Comparator: Part 1: mRNA-1273
Participants will receive 1 IM dose of mRNA-1273 on Day 1.
Biological: mRNA-1273
Sterile liquid for injection

Experimental: Part 2: mRNA-1273.214
Participants will receive 1 IM dose of mRNA-1273.214 on Day 1.
Biological: mRNA-1273.214
Sterile liquid for injection

Active Comparator: Part 2: mRNA-1273
Participants will receive 1 IM dose of mRNA-1273 on Day 1.
Biological: mRNA-1273
Sterile liquid for injection




Primary Outcome Measures :
  1. Geometric Mean Titer (GMT) of mRNA-1273.529 and mRNA-1273 Against the B.1.1.529 Strain [ Time Frame: Up to Day 179 post-vaccination ]
  2. Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs) [ Time Frame: Up to Day 8 (7 days post-vaccination) ]
  3. Number of Participants with Unsolicited Adverse Events (AEs) [ Time Frame: Up to Day 29 (28 days post-vaccination) ]
  4. Number of Participants with Serious AEs (SAEs) [ Time Frame: Day 1 to end of study (Day 359) ]
  5. Number of Participants with Medically Attended AEs (MAAEs) [ Time Frame: Day 1 to end of study (Day 359) ]
  6. Number of Participants with AEs Leading to Withdrawal [ Time Frame: Day 1 to end of study (Day 359) ]
  7. Number of Participants with AEs of Special Interest (AESIs) [ Time Frame: Day 1 to end of study (Day 359) ]
  8. GMT of mRNA-1273.214 and mRNA-1273 Against the B1.1.529 Strain [ Time Frame: Up to Day 179 post-vaccination ]
  9. GMT of mRNA-1273.214 and mRNA-1273 Against the Prototype Strain [ Time Frame: Up to Day 179 post-vaccination ]

Secondary Outcome Measures :
  1. GMT of mRNA-1273.529 and mRNA-1273 Against the B.1.1.529 Strain [ Time Frame: Days 1, 29, 85, 179, and 359 ]
  2. GMT of mRNA-1273.529 and mRNA-1273 Against the Prototype Strain [ Time Frame: Days 1, 29, 85, 179, and 359 ]
  3. GMFR of mRNA-1273.529 and mRNA-1273 Against the Prototype Strain [ Time Frame: Days 1, 29, 85, 179, and 359 ]
  4. GMFR of mRNA-1273.529 and mRNA-1273 Against the B.1.1.529 Strain [ Time Frame: Days 1, 29, 85, 179, and 359 ]
  5. Seroresponse Rate of Vaccine Recipients [ Time Frame: Days 1, 29, 85, 179, and 359 ]
  6. GMT of mRNA-1273.214 and mRNA-1273 Against Other Variant Strains [ Time Frame: Days 29, 85, and 179 ]
  7. GMT of mRNA-1273.214 Against the B.1.1.529 Strain [ Time Frame: Days 1, 29, 85, 179, and 359 ]
  8. GMT of mRNA-1273.214 Against the Prototype Strain [ Time Frame: Days 1, 29, 85, 179, and 359 ]
  9. GMFR of mRNA-1273.214 and mRNA-1273 Against the B.1.1.529 Strain [ Time Frame: Days 1, 29, 85, 179, and 359 ]
  10. GMFR of mRNA-1273.214 and mRNA-1273 Against the Prototype Strain [ Time Frame: Days 1, 29, 85, 179, and 359 ]
  11. Number of Participants with Asymptomatic SARS-CoV-2 Infection Measured by Reverse Transcriptase Polymerase-chain Reaction (RT-PCR) [ Time Frame: Day 1 to end of study (Day 359) ]
  12. Number of Participants with Symptomatic SARS-CoV-2 Infection Measured by RT-PCR [ Time Frame: Day 1 to end of study (Day 359) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Female participants of childbearing potential may be enrolled in the study if the participant has a negative pregnancy test at the Screening Visit and on the day of vaccination prior to vaccine dose being administered on Day 1; has practiced adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first dose (Day 1); and has agreed to continue adequate contraception through 90 days following vaccine administration.
  • Participant has received 2 prior doses of one of the following approved/authorized COVID-19 vaccines: Moderna, Pfizer/BioNTech, Oxford/AstraZeneca, Janssen. A heterologous vaccine regimen is acceptable.
  • Participants who will receive the 4th dose as part of the study must have previously received a mRNA vaccine (Moderna or Pfizer/BioNTech) as the 3rd dose of a COVID-19 vaccine. Participants who will receive the 3rd dose as part of the study may have previously received 2 doses of an approved/authorized mRNA or a non-mRNA COVID-19 vaccine (a heterologous vaccine regimen is acceptable).

Exclusion Criteria:

  • Participant had close contact (without personal protective equipment [PPE]) as defined by the Centers for Disease Control and Prevention (CDC) in the past 14 days to someone diagnosed with SARS-CoV-2 infection or COVID-19 within 10 days of the close contact. Participants may be rescreened after 14 days provided that they remain asymptomatic.
  • Participant is acutely ill or febrile (temperature ≥ 38.0°C/100.4°F) 72 hours prior to or at the Screening Visit or Day 1.
  • Participant has tested positive for SARS-CoV-2 by an authorized/approved lateral flow/rapid antigen or polymerase chain reaction (PCR) test within 90 days of Screening.
  • Participant has received a COVID-19 vaccine within 90 days of the Screening Visit.
  • Participant has received a total of 4 doses or more of COVID-19 vaccine.
  • Participant has received a COVID-19 vaccine at a dose different from the authorized/approved dose.
  • Any medical, psychiatric, or occupational condition, including reported history of substance abuse, that, in the opinion of the Investigator, might pose additional risk due to participation in the study or could interfere with the interpretation of study results.
  • Participant has received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 181 days prior to screening (for corticosteroids ≥10 milligrams [mg]/day of prednisone or equivalent) or is anticipating the need for immunosuppressive treatment at any time during participation in the study.
  • Participant has received or plans to receive any licensed vaccine ≤28 days prior to the study injection (Day 1) or plans to receive a licensed vaccine within 28 days after the study injection (with the exception that approved seasonal influenza vaccine may be received by at least 7 days and preferably 14 days apart from the study injection).
  • Participant has received systemic immunoglobulins or blood products within 90 days prior to the Screening Visit or plans to receive during the study.
  • Participant has donated ≥450 milliliters (mL) of blood products within 28 days prior to the Screening Visit or plans to donate blood products during the study.
  • Participant has participated in an interventional clinical study within 28 days prior to the Screening Visit based on the medical history interview or plans to do so while participating in this study.

Note: Other inclusion and exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05249829


Contacts
Layout table for location contacts
Contact: Moderna Clinical Trials Support Center 1-877-777-7187 clinicaltrials@modernatx.com

Locations
Show Show 29 study locations
Sponsors and Collaborators
ModernaTX, Inc.
Layout table for additonal information
Responsible Party: ModernaTX, Inc.
ClinicalTrials.gov Identifier: NCT05249829    
Other Study ID Numbers: mRNA-1273-P305
First Posted: February 22, 2022    Key Record Dates
Last Update Posted: April 18, 2022
Last Verified: April 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by ModernaTX, Inc.:
Spikevax
mRNA-1273
mRNA-1273 vaccine
mRNA-1273.529
mRNA-1273.529 vaccine
Omicron
SARS-CoV-2
SARS-CoV-2 Vaccine
Coronavirus
Messenger RNA
COVID-19
COVID-19 Vaccine
Moderna
Multivalent Vaccine
Variant Strains